| LAI New User | LAI Continuous User | LAI Total | Oral APT | Other Injectable/Unknown | Study Total |
---|
| n = 235 | n = 385 | n = 620 | n = 377 | n = 68 | N = 1065 |
---|
Schizophrenia |
Baseline | 214 | 385 | 599 | 281 | 64 | 944 |
Month 6 | 173 (80.8) | 326 (84.7) | 499 (83.3) | 230 (81.9) | 40 (62.5) | 769 (81.5) |
Month 12 | 156 (72.9) | 290 (75.3) | 446 (74.5) | 204 (72.6) | 32 (50.0) | 682 (72.2) |
- APT antipsychotic therapy, LAI long-acting injectable, NA not applicable
- Among the 599 patients with schizophrenia in the total LAI group, 482 were receiving PP LAI (174 new users; 308 continuous users) and 117 were receiving RLAI (40 new users; 77 continuous users)
- Values in parentheses are percentages unless otherwise specified
- New user was defined as a study patient who initiated PP LAI or RLAI treatment within 8 weeks (≤56 days) of the enrollment period
- Continuous user was defined as a study patient who initiated PP LAI or RLAI treatment more than 8 weeks (>56 days) after the enrollment visit